RECOMBINANT VACCINE FOR LYME DISEASE

描述（改编自申请人摘要）：免疫接种 伯氏疏螺旋体外表面蛋白（Osp）A或OspC 诱导保护性免疫，以随后的挑战与菌株 B。奥普氏菌就是从它衍生出来的 然而，OspA和 OspC是异质性的，对一种菌株的保护不 必须保护免受其他菌株的挑战。 的 研究人员建议开发一种多价疫苗， 保护。 在初步研究中，研究人员 构建了表达由OspA组成的蛋白质的嵌合基因， 来自疏螺旋体的选定菌株的OspC区段。 这些嵌合基因 将在E.大肠杆菌中作为脱脂蛋白嵌合体。 去脂蛋白质可以以比去脂蛋白质高得多的浓度产生。 脂化蛋白质 这些蛋白质中Cys残基的侧链 重组嵌合体将被化学修饰以引入脂质 膜锚 在第二阶段，合成脂蛋白嵌合体 将在动物模型中进行单独和组合测试， 评估它们在预防一系列疏螺旋体感染中的功效 菌株 调查人员预计，这将产生第二个 新一代人类疫苗，将提供更长的免疫持续时间 与目前临床试验中的候选疫苗相比， 拟议的商业应用：不可用。

DESCRIPTION (Adapted from the applicant's abstract): Immunization with either Borrelia burgdorferi outer surface protein (Osp) A or OspC induces protective immunity to subsequent challenge with the strain of B. burgdorferi from which the Osp's were derived. However, OspA and OspC are heterogeneous and protection against one strain does not necessarily protect against challenge with other strains. The investigators propose to develop a polyvalent vaccine with a board range of protection. In preliminary studies, the investigators have constructed chimeric genes that express proteins comprised of OspA and OspC segments from selected strains of Borrelia. These chimeric genes will be overexpressed in E. coli as unlipidated protein chimers. Unlipidated proteins can be produced at much higher concentrations than lipidated proteins. The side-chains of Cys residues in these recombinant chimers will be chemically modified to introduce lipid membrane anchors. During Phase II, the synthetic lipoprotein chimers will be tested in animal models, separately and in combination, to assess their efficacy in preventing infection with an array of Borrelia strains. The investigators expect that this will produce a second generation human vaccine that will provide a longer duration of immune protection compared to vaccine candidates currently in clinical trials. PROPOSED COMMERCIAL APPLICATION: Not available.